{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:25:34Z","timestamp":1790526334522,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T00:00:00Z","timestamp":1409184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"},{"start":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T00:00:00Z","timestamp":1409184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"DOI":"10.1038\/cddis.2014.346","type":"journal-article","created":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T13:05:06Z","timestamp":1409231106000},"page":"e1389-e1389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK"],"prefix":"10.1038","volume":"5","author":[{"given":"C","family":"Brosseau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Dousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ma\u00efga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Amiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Pellat-Deceunynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,28]]},"reference":[{"key":"BFcddis2014346_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0959-8049(01)00366-5","volume":"38","author":"NS Andersen","year":"2002","unstructured":"Andersen NS, Jensen MK, de Nully Brown P, Geisler CH . A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002; 38: 401\u2013408.","journal-title":"Eur J Cancer"},{"key":"BFcddis2014346_CR2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cncr.23608","volume":"113","author":"Y Zhou","year":"2008","unstructured":"Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008; 113: 791\u2013798.","journal-title":"Cancer"},{"key":"BFcddis2014346_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1053\/j.seminhematol.2011.06.002","volume":"48","author":"S Harel","year":"2011","unstructured":"Harel S, Delarue R, Ribrag V, Dreyling M, Hermine O . Treatment of younger patients with mantle cell lymphoma. Semin Hematol 2011; 48: 194\u2013207.","journal-title":"Semin Hematol"},{"key":"BFcddis2014346_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/bjh.12008","volume":"159","author":"HE Eve","year":"2012","unstructured":"Eve HE, Carey S, Richardson SJ, Heise CC, Mamidipudi V, Shi T et al. Single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012; 159: 154\u2013163.","journal-title":"Br J Haematol"},{"key":"BFcddis2014346_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pharmthera.2012.07.004","volume":"136","author":"B Pan","year":"2012","unstructured":"Pan B, Lentzsch S . The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther 2012; 136: 56\u201368.","journal-title":"Pharmacol Ther"},{"key":"BFcddis2014346_CR6","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"PH Wiernik","year":"2008","unstructured":"Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4952\u20134957.","journal-title":"J Clin Oncol"},{"key":"BFcddis2014346_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.beha.2012.04.005","volume":"25","author":"R Dawar","year":"2012","unstructured":"Dawar R, Hernandez-Ilizaliturri F . The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Best Pract Res Clin Haematol 2012; 25: 185\u2013190.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFcddis2014346_CR8","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622\u20131627.","journal-title":"Ann Oncol"},{"key":"BFcddis2014346_CR9","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013; 31: 3688\u20133695.","journal-title":"J Clin Oncol"},{"key":"BFcddis2014346_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1365-2141.2011.08882.x","volume":"155","author":"AA Chanan-Khan","year":"2011","unstructured":"Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol 2011; 155: 457\u2013467.","journal-title":"Br J Haematol"},{"key":"BFcddis2014346_CR11","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","volume":"116","author":"G Gorgun","year":"2010","unstructured":"Gorgun G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010; 116: 3227\u20133237.","journal-title":"Blood"},{"key":"BFcddis2014346_CR12","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1210\/er.2012-1000","volume":"33","author":"CJ Rosen","year":"2012","unstructured":"Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 2012; 33: 456\u2013492.","journal-title":"Endocr Rev"},{"key":"BFcddis2014346_CR13","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1056\/NEJMp1102022","volume":"364","author":"JE Manson","year":"2011","unstructured":"Manson JE, Mayne ST, Clinton SK . Vitamin D and prevention of cancer\u2013ready for prime time? N Engl J Med 2011; 364: 1385\u20131387.","journal-title":"N Engl J Med"},{"key":"BFcddis2014346_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jphotobiol.2010.04.008","volume":"101","author":"WB Grant","year":"2010","unstructured":"Grant WB . Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other cancers. J Photochem Photobiol B 2010; 101: 130\u2013136.","journal-title":"J Photochem Photobiol B"},{"key":"BFcddis2014346_CR15","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1200\/JCO.2010.28.6674","volume":"28","author":"MT Drake","year":"2010","unstructured":"Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN et al. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol 2010; 28: 4191\u20134198.","journal-title":"J Clin Oncol"},{"key":"BFcddis2014346_CR16","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/nrc2196","volume":"7","author":"KK Deeb","year":"2007","unstructured":"Deeb KK, Trump DL, Johnson CS . Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7: 684\u2013700.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2014346_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/mc.21999","volume":"53","author":"N Nemazannikova","year":"2013","unstructured":"Nemazannikova N, Antonas K, Dass CR . Vitamin D: Metabolism, molecular mechanisms, and mutations to malignancies. Mol Carcinog 2013; 53: 421\u2013431.","journal-title":"Mol Carcinog"},{"key":"BFcddis2014346_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s10495-011-0670-5","volume":"17","author":"C Brosseau","year":"2012","unstructured":"Brosseau C, Colston K, Dalgleish AG, Galustian C . The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics. Apoptosis 2012; 17: 164\u2013173.","journal-title":"Apoptosis"},{"key":"BFcddis2014346_CR19","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.1158\/1078-0432.CCR-11-0955","volume":"17","author":"C Touzeau","year":"2011","unstructured":"Touzeau C, Dousset C, Bodet L, Gomez-Bougie P, Bonnaud S, Moreau A et al. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high\/Mcl-1low profile and synergizes with other antineoplastic agents. Clin Cancer Res 2011; 17: 5973\u20135981.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2014346_CR20","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-12-0487","volume":"72","author":"S Surget","year":"2012","unstructured":"Surget S, Chiron D, Gomez-Bougie P, Descamps G, Menoret E, Bataille R et al. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res 2012; 72: 4562\u20134573.","journal-title":"Cancer Res"},{"key":"BFcddis2014346_CR21","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1038\/bjc.2013.186","volume":"108","author":"S Maiga","year":"2013","unstructured":"Maiga S, Gomez-Bougie P, Bonnaud S, Gratas C, Moreau P, Le Gouill S et al. Paradoxical effect of lenalidomide on cytokine\/growth factor profiles in multiple myeloma. Br J Cancer 2013; 108: 1801\u20131806.","journal-title":"Br J Cancer"},{"key":"BFcddis2014346_CR22","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1038\/sj.bjc.6605981","volume":"103","author":"L Bodet","year":"2010","unstructured":"Bodet L, Menoret E, Descamps G, Pellat-Deceunynck C, Bataille R, Le Gouill S et al. BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma. Br J Cancer 2010; 103: 1808\u20131814.","journal-title":"Br J Cancer"},{"key":"BFcddis2014346_CR23","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.3109\/10428194.2012.661854","volume":"53","author":"E Hatzimichael","year":"2012","unstructured":"Hatzimichael E, Dasoula A, Kounnis V, Benetatos L, Lo Nigro C, Lattanzio L et al. Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed\/refractory disease with therapeutic implications. Leuk Lymphoma 2012; 53: 1709\u20131713.","journal-title":"Leuk Lymphoma"},{"key":"BFcddis2014346_CR24","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26: 2326\u20132335.","journal-title":"Leukemia"},{"key":"BFcddis2014346_CR25","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"YX Zhu","year":"2011","unstructured":"Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771\u20134779.","journal-title":"Blood"},{"key":"BFcddis2014346_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1083\/jcb.200703040","volume":"179","author":"B Gillissen","year":"2007","unstructured":"Gillissen B, Essmann F, Hemmati PG, Richter A, Oztop I, Chinnadurai G et al. Mcl-1 determines the Bax dependency of Nbk\/Bik-induced apoptosis. J Cell Biol 2007; 179: 701\u2013715.","journal-title":"J Cell Biol"},{"key":"BFcddis2014346_CR27","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.1158\/0008-5472.CAN-05-4552","volume":"66","author":"TY Kim","year":"2006","unstructured":"Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD . Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 2006; 66: 7490\u20137501.","journal-title":"Cancer Res"},{"key":"BFcddis2014346_CR28","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/cdd.2009.13","volume":"16","author":"A Ritchie","year":"2009","unstructured":"Ritchie A, Gutierrez O, Fernandez-Luna JL . PAR bZIP-bik is a novel transcriptional pathway that mediates oxidative stress-induced apoptosis in fibroblasts. Cell Death Differ 2009; 16: 838\u2013846.","journal-title":"Cell Death Differ"},{"key":"BFcddis2014346_CR29","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/sj.cdd.4401782","volume":"13","author":"I Sturm","year":"2006","unstructured":"Sturm I, Stephan C, Gillissen B, Siebert R, Janz M, Radetzki S et al. Loss of the tissue-specific proapoptotic BH3-only protein Nbk\/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ 2006; 13: 619\u2013627.","journal-title":"Cell Death Differ"},{"key":"BFcddis2014346_CR30","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","volume":"13","author":"M Wang","year":"2012","unstructured":"Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. Lancet Oncol 2012; 13: 716\u2013723.","journal-title":"Lancet Oncol"},{"key":"BFcddis2014346_CR31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3109\/10428194.2012.733882","volume":"54","author":"M Dreyling","year":"2012","unstructured":"Dreyling M, Kluin-Nelemans HC, Bea S, Klapper W, Vogt N, Delfau-Larue MH et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma 2012; 54: 699\u2013707.","journal-title":"Leuk Lymphoma"},{"key":"BFcddis2014346_CR32","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1093\/emboj\/cdg343","volume":"22","author":"B Gillissen","year":"2003","unstructured":"Gillissen B, Essmann F, Graupner V, Starck L, Radetzki S, Dorken B et al. Induction of cell death by the BH3-only Bcl-2 homolog Nbk\/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J 2003; 22: 3580\u20133590.","journal-title":"EMBO J"},{"key":"BFcddis2014346_CR33","doi-asserted-by":"publisher","first-page":"18053","DOI":"10.1074\/jbc.M201235200","volume":"277","author":"M Germain","year":"2002","unstructured":"Germain M, Mathai JP, Shore GC. BH-3-only BIK functions at the endoplasmic reticulum to stimulate cytochrome c release from mitochondria. J Biol Chem 2002; 277: 18053\u201318060.","journal-title":"J Biol Chem"},{"key":"BFcddis2014346_CR34","doi-asserted-by":"publisher","first-page":"23829","DOI":"10.1074\/jbc.M500800200","volume":"280","author":"JP Mathai","year":"2005","unstructured":"Mathai JP, Germain M, Shore GC, BH3-only BIK . regulates BAX,BAK-dependent release of Ca2+ from endoplasmic reticulum stores and mitochondrial apoptosis during stress-induced cell death. J Biol Chem 2005; 280: 23829\u201323836.","journal-title":"J Biol Chem"},{"key":"BFcddis2014346_CR35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1074\/jbc.M110.167148","volume":"286","author":"H Du","year":"2011","unstructured":"Du H, Wolf J, Schafer B, Moldoveanu T, Chipuk JE, Kuwana T . BH3 domains other than Bim and Bid can directly activate Bax\/Bak. J Biol Chem 2011; 286: 491\u2013501.","journal-title":"J Biol Chem"},{"key":"BFcddis2014346_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1182\/blood-2006-06-026500","volume":"109","author":"C Mestre-Escorihuela","year":"2007","unstructured":"Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R, Climent J, Fresquet V et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007; 109: 271\u2013280.","journal-title":"Blood"},{"key":"BFcddis2014346_CR37","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/sj.onc.1208300","volume":"24","author":"H Tagawa","year":"2005","unstructured":"Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005; 24: 1348\u20131358.","journal-title":"Oncogene"},{"key":"BFcddis2014346_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","volume":"117","author":"P Perez-Galan","year":"2011","unstructured":"Perez-Galan P, Dreyling M, Wiestner A . Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117: 26\u201338.","journal-title":"Blood"},{"key":"BFcddis2014346_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/icb.2011.100","volume":"90","author":"O Khan","year":"2012","unstructured":"Khan O, La Thangue NB . HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90: 85\u201394.","journal-title":"Immunol Cell Biol"},{"key":"BFcddis2014346_CR40","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.cellsig.2011.02.003","volume":"23","author":"J Ren","year":"2011","unstructured":"Ren J, Singh BN, Huang Q, Li Z, Gao Y, Mishra P et al. DNA hypermethylation as a chemotherapy target. Cell Signal 2011; 23: 1082\u20131093.","journal-title":"Cell Signal"},{"key":"BFcddis2014346_CR41","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3892\/ol.2012.1054","volume":"5","author":"K Kim","year":"2013","unstructured":"Kim K, An S, Cha HJ, Choi YM, Choi SJ, An IS et al. Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells. Oncol Lett 2013; 5: 588\u2013592.","journal-title":"Oncol Lett"},{"key":"BFcddis2014346_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2012-05-428573","volume":"121","author":"CJ Hickey","year":"2013","unstructured":"Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A et al. Lenalidomide-mediated enhanced translation of C\/EBPalpha-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood 2013; 121: 159\u2013169.","journal-title":"Blood"},{"key":"BFcddis2014346_CR43","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.4161\/cc.11.6.19508","volume":"11","author":"F Pereira","year":"2012","unstructured":"Pereira F, Barbachano A, Singh PK, Campbell MJ, Munoz A, Larriba MJ . Vitamin D has wide regulatory effects on histone demethylase genes. Cell Cycle 2012; 11: 1081\u20131089.","journal-title":"Cell Cycle"},{"key":"BFcddis2014346_CR44","doi-asserted-by":"publisher","first-page":"18347","DOI":"10.1074\/jbc.R110.205286","volume":"286","author":"ZX Chen","year":"2011","unstructured":"Chen ZX, Riggs AD . DNA methylation and demethylation in mammals. J Biol Chem 2011; 286: 18347\u201318353.","journal-title":"J Biol Chem"}],"container-title":["Cell Death & Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis2014346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2014346","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2014346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:10:30Z","timestamp":1672960230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2014346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,28]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,8]]}},"alternative-id":["BFcddis2014346"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2014.346","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,28]]},"assertion":[{"value":"17 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}